Abbott Laboratories (ABT) Holds Near $103.70 with +2.6% Gain as Nutrition Split Takes Shape
Key Takeaways
- Abbott Laboratories (ABT) traded near $103.70 in late October 2026, up roughly 2.6% over the trailing 30 days after a choppy stretch for the stock.
- The shares pulled back from above $116 in late August to the mid-$90s in early October before stabilizing and recovering modestly into earnings season.
- Third-quarter 2026 revenue rose 14.5% year over year to $13.01 billion, with comparable sales up 7.0% and adjusted EPS of $1.42.
- Abbott announced plans to separate its Nutrition business into an independent public company, expected to be completed by the end of 2027.
- Management lowered full-year 2026 comparable sales growth guidance to approximately 6% and narrowed adjusted EPS guidance to $5.50–$5.55.
- BTIG lowered its price target to $125 from $134 while maintaining a Buy rating following the third-quarter report.
- For deeper research, explore Abbott's Price Targets, Earnings, and Forecast pages.
- Discover automated trading strategies on Tickeron's Trending AI Robots page.
Where Abbott Stands in the Current Market
Abbott shares have been consolidating after a noticeable late-summer pullback. The stock traded above $116 in late August 2026 before declining through September and reaching the mid-$90s in early October. That drawdown aligned with broader defensive-sector shifts and softer sentiment heading into third-quarter results. Over the past 30 days, however, the stock has recovered about 2.6%, moving from near $101 to roughly $103.70, as investors absorbed the quarterly report and the newly announced portfolio changes. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. The reaction points to a measured market view: Abbott’s underlying growth remains solid, yet near-term pressures in diabetes care and electrophysiology have kept enthusiasm in check.
Abbott Laboratories’ Business Overview and Competitive Position
Abbott Laboratories operates as a diversified global healthcare company across four main segments: Medical Devices, Diagnostics, Established Pharmaceuticals, and Nutrition. It is best known for the FreeStyle Libre continuous glucose monitoring franchise, along with cardiovascular, electrophysiology, and neuromodulation devices. Its Diagnostics business, bolstered by the Exact Sciences acquisition, covers core laboratory, molecular, and cancer diagnostics, including the Cologuard test. Nutrition brands such as Similac, Ensure, and Pedialyte complete a portfolio that delivers balanced, recurring revenue across developed and emerging markets. This diversification provides defensive cash-flow traits and several innovation-led growth paths, which explains why the stock attracts both growth and income investors.
Recent Developments Influencing ABT
The biggest development over the past month was Abbott’s plan to separate its Nutrition business into an independent public company by the end of 2027. That segment generates roughly $8.5 billion in annual sales, and management expects the separation to boost overall sales growth by 50–100 basis points while lifting operating margins by about 100 basis points. The decision reflects a sharper focus on higher-growth healthcare areas, though lingering litigation tied to infant nutrition will remain a factor for both entities.
Third-quarter earnings, released October 21, 2026, also influenced sentiment. Comparable sales rose 7.0%, with Medical Devices up 7.8% on a comparable basis and Diagnostics up 6.4%. Electrophysiology grew 15.5%, supported by the Volt pulsed field ablation catheter, while cancer diagnostics advanced 13.8% on Cologuard and precision oncology strength. Management did reduce full-year comparable sales growth guidance to about 6% from the prior 6.5%–7.5% range, pointing to temporary headwinds in electrophysiology and diabetes care. Diabetes growth is now expected to slow to low-to-mid single digits due to international pricing pressure and limited type 2 reimbursement expansion, while electrophysiology contends with softer left atrial appendage demand ahead of the Amulet 360 launch. Regulatory progress continued with FDA approval of the Libre Duo dual glucose-ketone sensor in August and the TactiFlex Duo ablation catheter in September, plus the launch of the SimpleScreen CRC blood-based colorectal cancer screening test.
Outlook for the Rest of 2026 and Key Areas to Monitor
Several factors will shape Abbott’s path forward. Execution and timing of the Nutrition separation will stay central, with investors watching for details on capital structure, dividend policy, and the standalone entity’s financial profile. Diabetes care remains a key variable: the planned U.S. launch of Libre Duo in December 2026 and a favorable payer formulary win effective January 1, 2027 could support renewed growth, while international pricing pressure lingers as a near-term headwind. In electrophysiology, the Amulet 360 device launch and continued Volt and TactiFlex Duo adoption will be closely tracked. Diagnostics, especially cancer diagnostics, will hinge on Cologuard momentum and integration of the Exact Sciences portfolio. Additional considerations include China volume-based procurement pressures, ongoing infant nutrition litigation, and how management frames 2027 guidance when it is provided in January. These elements present a balanced set of execution risks and innovation-driven opportunities. From what I see, the company’s diversified base continues to offer resilience.
Exploring Automated Strategies with Tickeron
In my own analysis, I frequently turn to Tickeron’s Trending AI Robots to review automated trading strategies. The page curates top-performing bots from a larger library, allowing comparison across different approaches and timeframes for names like ABT. This offers a practical way to examine data-driven ideas alongside fundamental research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABT in +3.17% Uptrend, growing for three consecutive days on October 23, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABT advanced for three days, in 170 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ABT's RSI Indicator exited the oversold zone, 19 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 51%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on ABT as a result. In 43 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.
The Moving Average Convergence Divergence (MACD) for ABT just turned positive on October 09, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in 25 of 54 cases over the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 54 cases where ABT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ABT broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ABT entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.511) is normal, around the industry mean (2.914). P/E Ratio (33.452) is within average values for comparable stocks, (1.904). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.052). Dividend Yield (0.024) settles around the average of (0.009) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care products
Industry MedicalNursingServices
Advertisement